{
    "clinical_study": {
        "@rank": "121231", 
        "brief_summary": {
            "textblock": "To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir,\n      indinavir and nelfinavir after multiple oral dosing. To determine the steady-state\n      pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after\n      multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when\n      combined with saquinavir, indinavir and nelfinavir."
        }, 
        "brief_title": "A Study of 141W94 in Combination With Other Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomized to receive open label 141W94 in combination with saquinavir,\n      indinavir and nelfinavir. The randomized phase will be preceded by a single dose\n      pharmacokinetic interaction study of 141W94 and indinavir in 12 patients. Data from this\n      single dose investigation will be used to determine the dose of indinavir to be used in the\n      randomized phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed provided used with caution:\n\n        Medications that may interact at CYP3A4 (either a substrate, inhibitor or inducer of the\n        enzyme) should be used with caution.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4+ cell count >= 200 cells/mm3.\n\n             1. Anticipated need for treatment with cytotoxic chemotherapeutic agents within the\n             study time period.\n\n          -  Treatment with immunomodulating agents.\n\n          -  Medications that should not be administered with 141W94:\n\n        Terfenadine. Astemizole. Cisapride. Triazolam. Midazolam.\n        Ergotamine/Dihydroergotamine-containing regimens. Antiretroviral drugs. Vitamin E\n        supplements. Other experimental agents.\n\n        Anticipated need for radiation therapy within the study time period.\n\n        1. Prior protease inhibitors.\n\n          -  Antiretroviral therapy within 2 weeks prior to entry.\n\n          -  Treatment with cytotoxic chemotherapeutic agents within 4 weeks prior to entry.\n\n        Radiation therapy within 4 weeks prior to entry. Current alcohol or illicit drug use that,\n        in the opinion of the investigator, may interfere with the patient's ability to comply\n        with the dosing and protocol evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "48", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002372", 
            "org_study_id": "264A"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Saquinavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Saquinavir", 
                "Nelfinavir", 
                "Amprenavir", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Administration, Oral", 
            "HIV Protease Inhibitors", 
            "Indinavir", 
            "Saquinavir", 
            "Nelfinavir", 
            "VX 478"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "Univ of California / San Diego Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "11391165", 
            "citation": "Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L, Tisdale M. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):458-61."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002372"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Univ of California / San Diego Treatment Ctr": "32.715 -117.157", 
        "Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr": "35.994 -78.899", 
        "ViRx Inc": "37.775 -122.419"
    }
}